Mayo Clinic Laboratories now offers a comprehensive addiction rehabilitation monitoring profile, an innovative assay that employs a combination of technologies to test urine for the most commonly used substances. In this test specific episode of the "Answers From the Lab" podcast, Loralie Langman, Ph.D., and Paul Jannetto, Ph.D., discuss the test’s utility to help guide and monitor treatment.

“Urine drug testing has been referred to as the technology of addiction treatment,” Dr. Jannetto says. “It’s not meant to be punitive, but rather as a tool to support recovery and provide motivation or reinforcement for abstinence.”

Developed for clinicians who manage complex patients struggling with substance use disorders to common substances such as opioids, marijuana, alcohol, and nicotine, the addiction monitoring profile offers improved specificity and includes adulterant testing and enhanced reports. Listen to learn more about how our testing enables accurate answers and simplified results to clarify patients’ substance use.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

ADMPU | Addiction Medicine Profile with Reflex, 22 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine

Useful information

• Assessing patients at-risk for substance use disorders.
• Detecting drug use involving stimulants, barbiturates, benzodiazepines, cocaine, opioids, tetrahydrocannabinol, alcohol, and nicotine.
• This test is not intended for use in employment-related testing.

Specimen requirements

Specimen Type: Urine Container, 60 mL (T313)

Specimen Volume: 30 mL

Container/Tube: Plastic urine container

Collection Instructions:

• Collect a random urine specimen.
• Submit 30 mL in 1 plastic bottle.
• No preservative.

Additional Information:

• No specimen substitutions.
• Submitting less than 30 mL may compromise the ability to perform all necessary testing.
• STATS are not accepted for this procedure.

Performance information

Analytic time: 2 to 5 days 

Days performed: Varies

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less